While ENTPD2 overexpression was a poor predictor of prognosis for HCC, ENTPD2 inhibition was able to slow the progression of the tumor and improve the effectiveness and efficiency of immune checkpoint inhibitors [41]. Here, ENTPD2 is linked to hepatocellular carcinoma.